Iron-based phosphate binders: a paradigm shift in the treatment of hyperphosphatemic anemic CKD patients?
The partial correction of anemia and the normalization of phosphate and blood pressure are the mainstay of treatment of patients with chronic kidney disease (CKD). Available anti-hypertensive drugs, erythropoiesis stimulating agents (ESAs) and iron supplements have resolved quite satisfactorily the goal of controlling hypertension and partially correcting anemia. Unfortunately, the treatment of hyperphosphatemia is still far from resolved. Phosphate binders have poor tolerability and/or limited efficacy, leading to the prescription of many tablets that achieve only a mild-to-moderate effect. Moreover, increased consumption of tablets is associated with increased low tolerability, thus jeopardizing patient compliance and, in turn, the efficacy of phosphate binding. Compared to calcium-free binders, the cheaper calcium salts increase the risk of hypercalcemia, calciphylaxis and vascular calcification and possibly all-cause mortality. Calcium-free phosphate binders decrease serum phosphate levels without increasing the serum calcium concentration. The higher phosphate-binding efficacy of lanthanum carbonate compared to sevelamer should be balanced against its lack of pleiotropic effects on lipid metabolism and inflammation and the accumulation in bones. New iron-based phosphate binders are available. In addition to their phosphate binding capacity, they could also be useful to treat anemia. Iron citrate is seeking for such an indication because its iron absorption is significant. This could be of clinical importance, particularly in CKD patients not on dialysis, obviating the need for extra oral iron administration and possibly favoring compliance. In conclusion, the use of iron-based phosphate binders with significant iron absorption properties could represent a novel paradigm for correcting anemia and hyperphosphatemia in CKD patients.
KeywordsAnaemia Hyperphosphatemia Iron Phosphate binders Chronic kidney disease Iron citrate
Compliance with ethical standrads
This article does not contain any studies with human participants performed by any of the authors.
Conflict of interest
No funding was obtained for this paper. F Locatelli is or was a member of an advisory board and/or speaker at symposia sponsored by Amgen, Keryx, Roche, Astellas, Akebia and Vifor-Fresenius Pharma. L Del Vecchio was a member of Advisory Boards for Roche and Astellas.
- 1.Kidney Disease: Improving Global Outcomes (KDIGO) CKD MBD Work Group (2009). KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 113:S1–S130Google Scholar
- 11.Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group (2013) KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 3(4),1–150Google Scholar
- 12.Palmer SC, Hayen A, Macaskill P, Pellegrini F, Craig JC, Elder GJ, Strippoli GF (2011) Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. JAMA 305(11):1119–1127CrossRefPubMedGoogle Scholar
- 21.Locatelli F, Del Vecchio L (2014) Optimal phosphate control: still an unmet need in chronic kidney disease patients. Expert Opin Pharmacother 13(5):551–561Google Scholar
- 22.Habbous S, Przech S, Acedillo R, Sarma S, Garg AX, Martin J (2017) The efficacy and safety of sevelamer and lanthanum versus calcium-containing and iron-based binders in treating hyperphosphatemia in patients with chronic kidney disease: a systematic review and meta-analysis. Nephrol Dial Transplant 32(1):111–125PubMedGoogle Scholar
- 33.Phan O, Maillard M, Malluche HH, Stehle JC, Funk F, Burnier M (2015) Effects of sucroferric oxyhydroxide compared to lanthanum carbonate and sevelamer carbonate on phosphate homeostasis and vascular calcifications in a rat model of chronic kidney failure. Biomed Res Int 2015:515606Google Scholar
- 47.McIntyre CW, Pai P, Warwick G, Wilkie M, Toft AJ, Hutchison AJ (2009) Iron-magnesium hydroxycarbonate (fermagate): a novel non-calcium-containing phosphate binder for the treatment of hyperphosphatemia in chronic hemodialysis patients. Clin J Am Soc Nephrol 4(2):401–409CrossRefPubMedPubMedCentralGoogle Scholar
- 54.Koiwa F, Yokoyama K, Fukagawa M, Terao A, Akizawa T (2017) Efficacy and safety of sucroferric oxyhydroxide compared with sevelamer hydrochloride in Japanese haemodialysis patients with hyperphosphataemia: a randomized, open-label, multicentre, 12-week phase III study. Nephrology (Carlton) 22(4):293–300CrossRefGoogle Scholar
- 58.Covic AC, Floege J, Ketteler M et al (2016) Iron-related parameters in dialysis patients treated with sucroferric oxyhydroxide. Nephrol Dial Transplant (pii: gfw242, Epub ahead of print) Google Scholar
- 65.Fishbane S, Block GA, Loram L, Neylan J, Pergola PE, Uhlig K, Chertow GM (2017) Effects of ferric citrate in patients with nondialysis-dependent CKD and iron deficiency anemia. J Am Soc Nephrol (Epub ahead of print) Google Scholar
- 66.Umanath K, Greco B, Jalal DI et al (2017) The safety of achieved iron stores and their effect on IV iron and ESA use: post-hoc results from a randomized trial of ferric citrate as a phosphate binder in dialysis. Clin Nephrol (Epub ahead of print) Google Scholar
- 74.Van Buren PN, Lewis JB, Dwyer JP et al.; Collaborative Study Group (2015) The phosphate binder ferric citrate and mineral metabolism and inflammatory markers in maintenance dialysis patients: results from prespecified analyses of a randomized clinical trial. Am J Kidney Dis 66(3): 479–488CrossRefPubMedPubMedCentralGoogle Scholar
- 75.Greger JL (2007) Dietary and other sources of aluminium intake. In: Chadwick DJ, Whelan J (eds) Aluminium in biology and medicine (Novartis Foundation), 1st edn. Wiley, Chichester, pp 26–49Google Scholar
- 89.Koiwa F, Terao A (2016) Dose-response efficacy and safety of PA21 in Japanese hemodialysis patients with hyperphosphatemia: a randomized, placebo-controlled, double-blind, Phase II study. Clin Exp Nephrol (Epub ahead of print) Google Scholar